December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

6.730 +0.070 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Immuneering Stock Trading Higher On Tuesday? ↗
Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans. 
Via Benzinga
News headline image
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
From Immuneering Corporation
Via GlobeNewswire
News headline image
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore ↗
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Why is Immuneering (IMRX) Stock Up 24% Today? ↗
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus. 
Via InvestorPlace
News headline image
Immuneering Launches Pancreatic Cancer Advisory Board
From Immuneering Corporation
Via GlobeNewswire
News headline image
Top Trade Picks Of The Day: Don’t Miss These Market Movers ↗
Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
News headline image
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
News headline image
Why Is Nanocap Immuneering Stock Trading Higher On Friday? ↗
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate... 
Via Benzinga
News headline image
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Nasdaq Surges 1%; Meta Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 ↗
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
News headline image
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.